

The CCS is committed to preserving the scientific integrity of its Guidelines, Clinical Practice Updates and Position Statements through transparency and management of disclosures (industry, academic, financial benefits and other conflicts). Invited and approved panel members must disclose all relationships regardless of relevance to the topic. When a potential conflict exists, the affected member must recuse during the formal consensus voting process. For more information on the CCS Guideline Development process, please visit www.ccs.ca. Updated March 8, 2023.

Affiliations with commercial organizations or clinical trials within the previous two years that may have a direct or indirect connection to the content of this statement are disclosed here.

Members		Consulting Fees / Honoraria	Clinical Trials	Other Financial Benefits	Relevance to Statement
Panel members					
Primary Panel					
First name	Last name				
Ross A.	Davies	None	None	None	
Ciorsti	MacIntyre	Abbott Canada, Medtronic	None	None	
M. Sean	McMurtry	Bayer	AstraZeneca	None	No Relationship
Virginie	Beauséjour Ladouceur	None	None	None	
Martin	Green	Medtronic	None	None	No relation; speaker honoraria
Jacqueline	Joza	Boston Scientific	Medtronic	None	No relationship
David	Juurlink	None	None	None	
Andrew D.	Krahn	None	None	None	
Jason D.	Roberts	None	None	None	
Thomas M.	Roston	None	None	None	
Shubhayan	Sanatani	Xenon (consultant), Emtelligent (Medical Advisor)	None	None	The consulting work I have done for Xenon is related to my expertise in long QT but in a different population. They are developing a medication for a seizure disorder and wanted my guidance. I do not think it has any relevance to the proposed document. The work with Emtelligent has nothing to do with inherited heart rhythm work.
Christian	Steinberg	None	None	None	